Kiniksa Pharmaceuticals International vs Legend Biotech
Legend Biotech is the larger business, with $1.03bn of revenue in fiscal 2025 against $678m for Kiniksa Pharmaceuticals International (1.5 times as much). Legend Biotech grew faster (64.0% against 60.1%). Kiniksa Pharmaceuticals International kept more of each dollar of sales as profit: a net margin of 8.7% against -28.8%. Kiniksa Pharmaceuticals International carries less debt relative to equity (0.0% against 31.8%).
| Latest fiscal year | Kiniksa Pharmaceuticals InternationalKNSA, 2025 | Legend BiotechLEGN, 2025 |
|---|---|---|
| Revenue | $678m | $1.03bn |
| Revenue growth | 60.1% | 64.0% |
| Net income | $59.0m | −$297m |
| Operating margin | 11.4% | -13.3% |
| Net margin | 8.7% | -28.8% |
| Return on equity | 11.7% | -29.1% |
| Free cash flow | $136m | −$129m |
| Cash | $166m | $902m |
| Total debt | $0 | $319m |
| Debt to equity | 0.0% | 31.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 366 | — |
| Market value | $7.91bn | $3.97bn |
| Price vs our value range | Above our value range | — |
| Moat score | 16 (Weak) | — |
| Insider trades, 12 months | 0 buys, 37 sales | 0 buys, 5 sales |